Biology Reference
In-Depth Information
[57] Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats
modulating antiviral T cells. Nature 2012;481(7381):394-8.
[58] Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ, et al. A pilot study
of interleukin-2 for adult patients with acute myelogenous leukemia in first complete
remission. Cancer 1999;85(7):1506-13.
[59] Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, et al. IL-2-based
immunotherapy after autologous transplantation for lymphoma and breast cancer
induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Trans-
plant 2003;32:177-86.
[60] Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of natural
killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.
Blood 1999;94(1):333-9.
[61] Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor natural kill-
er cell allorecognition of missing self in haploidentical hematopoietic transplantation
for acute myeloid leukemia: challenging its predictive value. Blood 2007;110(1):433-40.
[62] Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al. Survival
advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation
from unrelated donors. Blood 2003;102(3):814-9.
[63] Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, et al. Evaluation of
KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants:
killer immunoglobulin-like receptor. Blood 2002;100(10):3825-7.
[64] Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, et al. The effect of
KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report
from the center for international blood and marrow transplant research, the European
blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Trans-
plant 2006;12(8):876-84.
[65] Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, et al. Improved out-
come in HLA-identical sibling hematopoietic stem-cell transplantation for acute my-
elogenous leukemia predicted by KIR and HLA genotypes. Blood 2005;105(12):4878-84.
[66] Lowe EJ, Turner V, Handgretinger R, Horwitz EM, Benaim E, Hale GA, et al. T-cell allore-
activity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-
non-identical paediatric bone marrow transplantation. Br J Haematol 2003;123(2):323-6.
[67] Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R, et al.
Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility
enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic
stem cell transplantation in patients with myeloid leukemias. Blood 2005;105(6):
2594-600.
[68] Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G, et al. KIR-ligand in-
compatibility in the graft-versus-host direction improves outcomes after umbilical cord
blood transplantation for acute leukemia. Leukemia 2009;23(3):492-500.
[69] Brunstein CG, Wagner JE, Weisdorf DJ, Cooley S, Noreen H, Barker JN, et al. Negative
effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on
transplantation conditioning intensity. Blood 2009;113(22):5628-34.
[70] Ruggeri L, Mancusi A, Burchielli E, Perruccio K, Aversa F, Martelli MF, et al. Natural
killer cell recognition of missing self and haploidentical hematopoietic transplantation.
Semin Cancer Biol 2006;16(5):404-11.
[71] Pando MJ, Gardiner CM, Gleimer M, McQueen KL, Parham P. The protein made
from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces
due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol
2003;171(12):6640-9.
[72] Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P. MHC class I-specific
inhibitory receptors and their ligands structure diverse human NK-cell repertoires
toward a balance of missing self-response. Blood 2008;112(6):2369-80.
[73] Foley BA, De Santis D, Van Beelen E, Lathbury LJ, Christiansen FT, Witt CS. The reactiv-
ity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor
suitability for haploidentical stem cell transplantations. Blood 2008;112(2):435-43.
[74] Bari R, Bell T, Leung WH, Vong QP, Chan WK, Das Gupta N, et al. Significant func-
tional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood
2009;114(25):5182-90.
[75] Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic poly-
morphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger
receptor for HLA-C than KIR2DL3. J Immunol 2008;180(6):3969-79.
[76] Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, et al. Anti-
leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical
HSCT for pediatric patients: evaluation of the functional role of activating KIR and
redefinition of inhibitory KIR specificity. Blood 2009;113(13):3119-29.
353
Search WWH ::
Custom Search